한국금융신문

구독신청

'SamsungBiologics' 검색결과

Samsung Biologics Hits Earnings Peak — But Strike Cloud Dims the Outlook Editor's Note: Corporate value is shaped by a wide range of factors, and an objective assessment requires examining multiple variables. Korea Financial Times explores the current conditions, responses... 2026-04-24 금요일 | 양현우 기자
Samsung Biologics Hits Industry-First KRW 2 Trillion Operating Profit, Eyes KRW 3 Trillion Next [KFT Topic] Samsung Biologics has written a new chapter in history. Following its industry-first breakthrough of KRW 1 trillion in operating profit in 2023, the company has reached the KRW 2 trillion milestone ju... 2026-01-23 금요일 | 양현우 기자
Samsung Biologics, Yuhan-Backed AIMEDBIO Surges 300% on KOSDAQ Debut AIMEDBIO soared spectacularly on its first day of KOSDAQ listing, rising 300% from its offering price. AIMEDBIO, which made a successful debut, attracted early attention thanks to investments from Sam... 2025-12-08 월요일 | 양현우 기자
Samsung Biologics vs. Celltrion: Which Company Excels in Both Earnings and Employee Benefits? Samsung Biologics and Celltrion showed a gap in both first-half performance and employee benefits this year. Samsung Biologics outpaced Celltrion not only in revenue but also in areas such as parental... 2025-08-20 수요일 | 양현우 기자
‘Cash-Rich’ Samsung Biologics and SK Bioscience Accelerate Investments Amid Biotech Industry Downturn Samsung Biologics and SK Bioscience, leading contract development and manufacturing organizations (CDMOs) in South Korea’s biotech sector, are continuing bold investment strategies backed by solid fi... 2025-05-07 수요일 | 김나영 기자
Intensified Competition, Trump Risk, and Oversupply... Samsung Biologics CEO John Rim Faces Mounting Challenges Amid Uncertainty Even as Samsung Biologics (hereinafter referred to as Samsung Bio) continues its strong growth, aiming for annual revenue of KRW 5 trillion this year, uncertainties persist.Former U.S. President Donal... 2025-03-25 화요일 | 김나영 기자
John Rim’s 4 Years That Changed the Bio Landscape: From Latecomer to ‘Samsung’s Savior’ If you were to name the next-generation growth engine to follow semiconductors in the Samsung Group, it would undoubtedly be the bio business. While other core divisions faced downturns, Samsung Biolo... 2025-03-25 화요일 | 김나영 기자
Samsung Biologics Replaces CFO and R&D Head... Will It Find New Momentum This Year? "First, best, and largest"... these were the adjectives that followed Samsung Biologics (Samsung Bio) last year. In 2023, Samsung Bio became the first company in the pharmaceutical and biotech industr... 2025-02-10 월요일 | 김나영 기자
K-PharmaBio’s First 'KRW 4 Trillion Club' Member – Samsung Biologics Eyes KRW 5 Trillion with Unmatched Excellence in Capacity Samsung Biologics has rewritten the history of Korea's pharmaceutical and biotech industry with its record-breaking financial performance. The company surpassed KRW 4 trillion in annual revenue for th... 2025-01-24 금요일 | 김나영 기자

1

한국금융 포럼 사이버관

더보기

종합 BEST CLICK

Auto&Tech

더보기

FT카드뉴스

더보기

[그래픽 뉴스] ‘순대’가 경제용어라고? 순(純)대외자산, 한국의 진짜 해외자산은 얼마일까?

[그래픽 뉴스] ISA 대개편! 나에게 유리한 계좌는?

[그래픽 뉴스] 미국 증시 새로운 키워드 'MANGOS'

환전·로또·육아휴직까지 하반기부터 달라지는 제도 TOP11

[그래픽 뉴스] 은퇴후 30년 부모님 세대의 생존전략

더보기

더보기

FT도서

더보기

애드버토리얼

한국금융신문

발행소(주소) : 서울시 중구 다동길 46 다동빌딩 6층 한국금융신문사 ㅣ 사업자번호 : 202-81-39551
제호: 한국금융 ㅣ 발행.편집인 : 김봉국 ㅣ 대표번호 : 02)773-6300
신문사업 등록번호: 서울,다06555 ㅣ 신문사업 등록일자: 1992년 1월 29일 ㅣ 발행.편집인 : 김봉국 ㅣ 발행일자: 1992년 3월2일
인터넷신문 등록번호: 서울, 아03960 ㅣ 인터넷신문 등록·발행: 2015년 11월 3일 ㅣ 청소년보호책임자 : 문수희 실장
FNTIMES.COM의 모든 콘텐츠 및 기사는 저작권법의 보호를 받는 바, 무단 전재, 복사, 배포 등을 금합니다.
Copyrightⓒ 한국금융신문 All Rights Reserved.